Literature DB >> 7606354

Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep.

K M Stevenson1, K J Gibson, E R Lumbers.   

Abstract

1. The transplacental transfers of three drugs (enalapril, captopril and losartan) which block the renin angiotensin system and have different lipophilicities were studied in chronically catheterized foetal sheep (125-139 days gestation). 2. The ability of the foeto-placental unit to convert enalapril to enalaprilat was studied in two chronically catheterized foetuses. Enalapril (3 mg kg-1, 7.9 mumol kg-1) given i.v. to the foetuses abolished the foetal pressor response to 5 micrograms angiotensin I (AI) in one foetus and attenuated the pressor response in the other. 3. Enalapril (100 mg, 5.7 mumol kg-1) given i.v. to the ewe (n = 5) abolished the maternal pressor response to 2.5 micrograms AI (n = 1) and attenuated the maternal pressor response to 5 micrograms AI (n = 5, P < 0.001). The foetal pressor response to 5 micrograms AI (n = 2) and 10 micrograms AI (n = 3) did not change. The maternal and foetal pressor responses to angiotensin II (AII; n = 5) did not change. 4. Foetal pressor responses to 5 micrograms AI (n = 1) and 10 micrograms AI (n = 2) were attenuated within 11 min of their mothers (n = 3) being given i.v. captopril (15 mg, 1.5 mumol kg-1). Foetal pressor responses to 5 micrograms AII (n = 1) and to 10 micrograms AII (n = 2) did not change. 5. Losartan (100 mg, kg-1, 21.7 mumol kg-1) given i.v. to the foetus (n = 9) attenuated the foetal pressor response to 5 micrograms AII (P < 0.001) but the maternal pressor response to 5 micrograms AII did not change. 6. Losartan (100 mg, 21.7 MICROmol kg-1) given i.v. to the ewe (n = 5) attenuated the maternal pressor response to 5 microg AII (P <0.002) but the foetal pressor response to 5 microg AII did not change.7. It is concluded that the foeto-placental unit of the sheep can metabolize enalapril to enalaprilat.Captopril readily crosses the sheep placenta but enalapril and losartan do not. Thus, the transplacental transfer of these drugs does not parallel their lipid solubilities. Furthermore the results show that AT1 receptors are important in mediating the vasoconstrictor effects of AII in the foetus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606354      PMCID: PMC1510278          DOI: 10.1111/j.1476-5381.1995.tb13376.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Pulmonary angiotensin-converting enzyme. Structural and catalytic properties.

Authors:  M Das; R L Soffer
Journal:  J Biol Chem       Date:  1975-09-10       Impact factor: 5.157

2.  A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin.

Authors:  H Y Yang; E G Erdös; Y Levin
Journal:  Biochim Biophys Acta       Date:  1970-08-21

3.  Maternal and fetal distribution of drugs in pregnancy.

Authors:  B L Mirkin
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  Release of a prostaglandin E-like substance from canine kidney by bradykinin.

Authors:  J C McGiff; N A Terragno; K U Malik; A J Lonigro
Journal:  Circ Res       Date:  1972-07       Impact factor: 17.367

5.  Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.

Authors:  C S Sweet; D M Gross; P T Arbegast; S L Gaul; P M Britt; C T Ludden; D Weitz; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

6.  Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.

Authors:  S L Swartz; G H Williams; N K Hollenberg; T J Moore; R G Dluhy
Journal:  Hypertension       Date:  1979 Mar-Apr       Impact factor: 10.190

7.  Changes in expression of angiotensin receptor subtypes in the rat aorta during development.

Authors:  M Viswanathan; K Tsutsumi; F M Correa; J M Saavedra
Journal:  Biochem Biophys Res Commun       Date:  1991-09-30       Impact factor: 3.575

8.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

Authors:  D M Gross; C S Sweet; E H Ulm; E P Backlund; A A Morris; D Weitz; D L Bohn; H C Wenger; T C Vassil; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

9.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

10.  Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man.

Authors:  S L Swartz; G H Williams; N K Hollenberg; L Levine; R G Dluhy; T J Moore
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

View more
  4 in total

1.  Comparison of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation.

Authors:  A J Forhead; K Whybrew; P Hughes; F Broughton Pipkin; M Sutherland; A L Fowden
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes.

Authors:  Carlos A Dias; Evandro M Neto-Neves; Marcelo F Montenegro; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-02       Impact factor: 3.000

Review 3.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

4.  Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats.

Authors:  Tae Hwan Kim; Min Gi Kim; Soyoung Shin; Yong-Ha Chi; Soo-Heui Paik; Joo-Han Lee; Sun Dong Yoo; Yu Seok Youn; Jürgen B Bulitta; Sang Hoon Joo; Seok Won Jeong; Kwon-Yeon Weon; Beom Soo Shin
Journal:  BMC Pharmacol Toxicol       Date:  2016-07-26       Impact factor: 2.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.